GSK Posts New Data From Phase III Study on RSV Vaccine Arexvy

GSK plc (GSK) announced new data from the phase III AReSVi-006 (Adult Respiratory Syncytial Virus) study. The study evaluated the efficacy of a single dose of its respiratory syncytial virus (RSV) vaccine, Arexvy, for protection against lower respiratory tract disease (LRTD) caused by RSV in adults aged 60 years and older, including those who are at increased risk of the disease over three RSV seasons. New data from the above mentioned study showed that treatment with a single dose of Arexvy cumulative effi ...